Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients

Autor: Michelle A. Quan, Kwan-Keat Ang, Joseph M Tuscano, Mehrdad Abedi, Brian A. Jonas, Naseem S Esteghamat, Jeanna L Welborn, Paul R. Kaesberg, Aaron S Rosenberg

Publikováno v: Blood. 140:7203-7205

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::926a6e47baeda492f7f753ccaaa79118
https://doi.org/10.1182/blood-2022-162959

A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Autor: Brian A. Jonas, Jeanna L Welborn, Naseem S Esteghamat, Rasmus T Hoeg, Aaron S Rosenberg, Laura Molnar, Ashley Linh Dang-Chu, Susan L Stewart, Joseph M Tuscano

Publikováno v: Blood. 140:6213-6214

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba40a34dac615726fd4b140a6cae778d
https://doi.org/10.1182/blood-2022-168126

Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center

Autor: Tamer Othman, Benjamin N. Moskoff, Gwendolyn Ho, Matthew E. Tenold, Tali Azenkot, Margaret L. Krackeler, Samantha C. Fisch, Laura A. Potter, Paul R. Kaesberg, Jeanna L. Welborn, Ted Wun, Naseem S. Esteghamat, Rasmus T. Hoeg, Aaron S. Rosenberg, Mehrdad Abedi, Joseph M. Tuscano, Brian A. Jonas

Publikováno v: Leukemia Research. 119:106885

Hyper-CVAD is an established regimen for adult ALL that was developed at the MD Anderson Cancer Center (MDACC). However, results can vary across different institutions given the heterogeneity of patient populations and institutional practices. Moreov

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4761443c0b7b0667c06497131e90a648
https://doi.org/10.1016/j.leukres.2022.106885

A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Autor: Matthew E. Tenold, Naseem Esteghamat, Laura A. Potter, Benjamin N Moskoff, Tali Azenkot, Joseph Tuscano, Mehrdad Abedi, Aaron S. Rosenberg, Theodore Wun, Tamer Othman, Margaret Krackeler, Samantha C Fisch, Brian A. Jonas, Jeanna L Welborn, Rasmus T. Hoeg, Paul Kaesberg

Publikováno v: Blood. 138:4394-4394

Background Ponatinib, a third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI), + hyper-CVAD showed remarkable activity against Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and may be superior to chemotherapy + earlier

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::731b8261b5d76c06a9867a4010269e51
https://doi.org/10.1182/blood-2021-149276

Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: A novel variant of myeloid proliferative neoplasm with eosinophilia

Autor: Ruijun Jeanna Su, Brian A. Jonas, Jeanna L Welborn, Jeffrey P. Gregg, Mingyi Chen

Publikováno v: Human Pathology: Case Reports, Vol 5, Iss C, Pp 6-9 (2016)
Su, RJ; Jonas, BA; Welborn, J; Gregg, JP; & Chen, M. (2016). Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: A novel variant of myeloid proliferative neoplasm with eosinophilia. Human Pathology: Case Reports, 5, 6-9. doi: 10.1016/j.ehpc.2015.10.001. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/2vp4t0bx

© 2016 The Authors The 2008 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues introduced a category for myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Many

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::909a92b0b88d891fcee58def3499f2e9